Balyasny Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.4M | Sell |
17,835
-109,173
| -86% | -$111M | 0.02% | 778 |
|
|
2025
Q4 | $136M | Sell |
127,008
-101,271
| -44% | -$96.8M | 0.17% | 122 |
|
|
2025
Q3 | $174M | Sell |
228,279
-272,597
| -54% | -$203M | 0.22% | 81 |
|
|
2025
Q2 | $390M | Buy |
500,876
+348,740
| +229% | +$271M | 0.59% | 15 |
|
|
2025
Q1 | $126M | Buy |
152,136
+65,140
| +75% | +$54.2M | 0.21% | 88 |
|
|
2024
Q4 | $67.2M | Sell |
86,996
-30,641
| -26% | -$25.4M | 0.1% | 235 |
|
|
2024
Q3 | $104M | Buy |
117,637
+38,823
| +49% | +$34.9M | 0.17% | 119 |
|
|
2024
Q2 | $71.4M | Buy |
78,814
+4,019
| +5% | +$3.21M | 0.12% | 200 |
|
|
2024
Q1 | $58.2M | Sell |
74,795
-34,262
| -31% | -$24.4M | 0.1% | 263 |
|
|
2023
Q4 | $63.6M | Buy |
109,057
+104,797
| +2,460% | +$61.2M | 0.12% | 218 |
|
|
2023
Q3 | $2.29M | Buy |
+4,260
| New | +$2.2M | ﹤0.01% | 1340 |
|
|
2023
Q2 | – | Sell |
-82,410
| Closed | -$34.6M | – | 2559 |
|
|
2023
Q1 | $28.3M | Buy |
82,410
+81,358
| +7,734% | +$27.4M | 0.07% | 408 |
|
|
2022
Q4 | $385K | Sell |
1,052
-124,293
| -99% | -$44.1M | ﹤0.01% | 1923 |
|
|
2022
Q3 | $40.5M | Sell |
125,345
-354,506
| -74% | -$112M | 0.12% | 201 |
|
|
2022
Q2 | $156M | Buy |
+479,851
| New | +$144M | 0.51% | 17 |
|
|
2022
Q1 | – | Sell |
-103,994
| Closed | -$28.7M | – | 2673 |
|
|
2021
Q4 | $28.7M | Buy |
103,994
+76,251
| +275% | +$19.3M | 0.1% | 276 |
|
|
2021
Q3 | $6.41M | Buy |
+27,743
| New | +$6.85M | 0.03% | 737 |
|
|
2021
Q1 | – | Sell |
-310,461
| Closed | -$52.4M | – | 1942 |
|
|
2020
Q4 | $52.4M | Buy |
310,461
+90,341
| +41% | +$13.5M | 0.29% | 72 |
|
|
2020
Q3 | $32.6M | Buy |
+220,120
| New | +$34.1M | 0.24% | 102 |
|
|
2020
Q1 | – | Sell |
-390,482
| Closed | -$51.3M | – | 1356 |
|
|
2019
Q4 | $51.3M | Buy |
390,482
+386,680
| +10,170% | +$44.8M | 0.31% | 77 |
|
|
2019
Q3 | $425K | Sell |
3,802
-13,754
| -78% | -$1.53M | ﹤0.01% | 970 |
|
|
2019
Q2 | $1.95M | Sell |
17,556
-13,577
| -44% | -$1.6M | 0.01% | 886 |
|
|
2019
Q1 | $4.04M | Sell |
31,133
-452,947
| -94% | -$55.1M | 0.03% | 622 |
|
|
2018
Q4 | $56M | Buy |
484,080
+409,932
| +553% | +$45.8M | 0.4% | 48 |
|
|
2018
Q3 | $7.96M | Buy |
74,148
+67,240
| +973% | +$6.72M | 0.04% | 558 |
|
|
2018
Q2 | $589K | Sell |
6,908
-136,611
| -95% | -$11.2M | ﹤0.01% | 1299 |
|
|
2018
Q1 | $11.1M | Buy |
143,519
+21,457
| +18% | +$1.73M | 0.05% | 494 |
|
|
2017
Q4 | $10.3M | Buy |
122,062
+14,105
| +13% | +$1.2M | 0.03% | 632 |
|
|
2017
Q3 | $9.23M | Buy |
107,957
+89,424
| +483% | +$7.33M | 0.04% | 530 |
|
|
2017
Q2 | $1.52M | Sell |
18,533
-5,914
| -24% | -$482K | 0.01% | 997 |
|
|
2017
Q1 | $2.06M | Sell |
24,447
-3,561
| -13% | -$285K | 0.01% | 903 |
|
|
2016
Q4 | $2.06M | Sell |
28,008
-2,513,130
| -99% | -$187M | 0.01% | 876 |
|
|
2016
Q3 | $204M | Buy |
2,541,138
+2,330,615
| +1,107% | +$187M | 1.18% | 1 |
|
|
2016
Q2 | $16.6M | Sell |
210,523
-252,839
| -55% | -$19M | 0.11% | 254 |
|
|
2016
Q1 | $33.4M | Buy |
463,362
+274,432
| +145% | +$20.8M | 0.2% | 154 |
|
|
2015
Q4 | $15.9M | Sell |
188,930
-45,780
| -20% | -$3.8M | 0.11% | 252 |
|
|
2015
Q3 | $19.6M | Buy |
234,710
+113,237
| +93% | +$9.56M | 0.15% | 193 |
|
|
2015
Q2 | $10.1M | Buy |
+121,473
| New | +$9.26M | 0.06% | 388 |
|
|
2015
Q1 | – | Sell |
-114,393
| Closed | -$7.89M | – | 1017 |
|
|
2014
Q4 | $7.89M | Buy |
+114,393
| New | +$7.72M | 0.07% | 342 |
|
Other funds holding LLY
VCM
VPM
Balyasny Asset Management's LLY Position: Q1 2026 in Review
Balyasny Asset Management reduced its Eli Lilly (LLY) stake by 86% in Q1 2026, selling an estimated $111M and leaving 17,835 shares worth $16.4M. The position accounts for 0.02% of the portfolio, ranked #778.
Balyasny Asset Management first reported a position in LLY in Q4 2014 and has held it in 39 quarters since. The position peaked at $390M in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Balyasny Asset Management held 17,835 shares of Eli Lilly worth $16.4M as of Q1 2026.
- Balyasny Asset Management sold 109,173 Eli Lilly shares in Q1 2026, an estimated $111M.
- Eli Lilly made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #778 holding.
- Balyasny Asset Management first reported a position in Eli Lilly in Q4 2014 and has held it in 39 quarters since.
- Balyasny Asset Management's Eli Lilly position peaked at $390M in Q2 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.